We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Low-Cost Vietnamese Vaccine for Cholera

By Biotechdaily staff writers
Posted on 21 May 2002
A new vaccine against cholera that can be made in Vietnam for about US$0.20 a dose has shown promising results in two clinical trials in Vietnam. More...
The trials were conducted by scientists from Viet Nam, Sweden, the United States, the Republic of Korea, South Korea, and the World Health Organization (WHO, Geneva, Switzerland).

The two trials involved about 144 adults who were 17-25 years old and about 103 children who were 1-12 years old. The participants were divided into three groups and given two doses of either the locally produced vaccine, its Swedish counterpart, or placebo, with the doses separated by two weeks. The trial in children began only after the adult trial showed no important side effects. The researchers found that the vaccine was associated with no side effects and caused a better immune response in children than adults, for reasons that were not clear.

The responses were comparable to the responses to a Swedish vaccine that has been licensed for use in several European countries. Further studies are needed, say the researchers, to evaluate the clinical protection of the new vaccine.

Work was begun in Vietnam about 15 years ago on the production of a killed oral cholera whole-cell vaccine that could be used in Viet Nam's public health program. This vaccine was later modified so that it could also counter a new form of epidemic cholera that had emerged and is the vaccine used in the trial.




Related Links:
World Health Org.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.